In-silico designing of a potent ligand molecule against PTEN (Phosphatase and tensin homolog) implicated in Breast Cancer

Abstract

Breast cancer has been attributed to be the second most common malignancy in females worldwide after skin cancer associated with a significantly high mortality rate. Tumor suppressor genes have an indispensable role in maintaining genomic integrity as well as cell cycle regulation. Phosphatase and tensin homolog deleted on chromosome ten (PTEN) is one of the most frequently mutated human tumor suppressor genes, implicated in cell growth, survival, and suppressing tumor formation. As the tumor progresses to more advanced stages, genetic alterations tend to increase one such alteration is the mutation of the PTEN gene which is linked to programmed cell death and maintenance of cell cycle regulation. There is a syndrome known as Cowden syndrome associated with a high risk of breast cancer which is a result of an outcome of germline mutations in the PTEN gene. Loss of PTEN activity, either at the protein or genomic level, has been related to many primary and metastatic malignancies including breast cancer. This study focuses on developing a potential bioavailable ligand inhibitory molecule for PTEN, using a computer-aided drug design approach (CADD). A library of developed ligands consisting of 50 potential molecules was screened to find a potential candidate to be used for second generation drug development. Among them, LIG28 was adjudged as the most effective and potential PTEN inhibitor given its maximum binding affinity of ΔG -5.96Kcal/mole with a lower RMSD value. Carmer’s Rule of toxicity further revealed the compatibility and non-toxicity of the molecule. These observations underscore the importance of PTEN as a target in the development of tumorigenesis and the prognosis of breast cancer.

Computational Docking Study of the Phytochemical Constituent, Silybin (Silybum marianum) against SARS-CoV-2 Omicron Variant Spike Glycoprotein: An In-silico Approach

“…Based on our experimental calculations on ligand binding free energy, favoured interactions with protein atoms, the results of the study are consistent with those found in the existing literature. 31…”

In-silico designing of an inhibitor against mTOR FRB domain: Therapeutic implications against breast cancer

“…The cleft is shaped like a deep V, thanks to the FRB or FKBP12-rapamycin-binding domain, which also limits access to the substrate-binding region (Ram et al 2020). When rapamycin-FKBP12 binds to the FRB (Raghav et al 2022), it effectively blocks all access to the substrate-binding site (Sharma et al 2010). Besides aiding in a restriction to the active site, FRB also facilitates S6K1 (a ribosomal protein kinase) access to the active site, yielding increased kinase activity (Raghav et al 2020).…”